| Clinical data | |
|---|---|
| Trade names | Prohalone |
| Other names | Aloprogesterone; 6α-Fluoro-17α-bromoprogesterone; 6α-Fluoro-17α-bromopregn-4-ene-3,20-dione |
| Routes of administration | By mouth |
| Drug class | Progestogen; Progestin |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C21H28BrFO2 |
| Molar mass | 411.355 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Haloprogesterone, sold under the brand name Prohalone, is a progestin medication which was previously marketed by Ayerst but is now no longer available.
Haloprogesterone, also known as 6α-fluoro-17α-bromoprogesterone or as 6α-fluoro-17α-bromopregn-4-ene-3,20-dione, is a synthetic pregnane steroid and a halogenated derivative of progesterone. It is specifically a derivative of 17α-bromoprogesterone and is similar structurally to medrogestone (6-dehydro-6,17α-dimethylprogesterone), medroxyprogesterone acetate (6α-methyl-17α-acetoxyprogesterone), and various other progestins derived from progesterone.
Chemical syntheses of haloprogesterone have been published.
Haloprogesterone was synthesized in 1960 and was introduced for medical use by 1961.
Haloprogesterone is the generic name of the drug and its INN and USAN.
Haloprogesterone was marketed under the brand name Prohalone.